CG Oncology
CGON
79.47
-2.43
-2.97%
CG Oncology
US · CGON
#1929 by market cap
Listed 2024
79.47
-2.43
-2.97%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
About CG Oncology
CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Dallas, TX.
- Founded
- 2010
- CEO
- Mr. Arthur Kuan
- Employees
- 142
- Headquarters
- Dallas, Texas, United States of America
- Fiscal year end
- 12-31
- Website
- cgoncology.com
Company profile
- Exchange
- US
- Symbol
- CGON
- Market-cap rank
- #1929
- Listing date
- 2024-01-25
- Market cap
- 7.10B
- Float cap
- 5.48B
- Shares out
- 89.32M
- Float shares
- 68.92M
Sectors & themes
Biotechnology
Fractional Shares JP
Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.
CG Oncology discussion 0 comments